$BDPT
BIOADAPTIVES, INC.

2024 Q4 Form 10-Q Financial Statement

#000164033424001752 Filed on November 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00 $15.65K
YoY Change -100.0% 368.95%
Cost Of Revenue $0.00 $11.00K
YoY Change -100.0% 722.66%
Gross Profit $0.00 $4.650K
YoY Change -100.0% 132.5%
Gross Profit Margin 29.71%
Selling, General & Admin $59.22K
YoY Change -20.58%
% of Gross Profit 1273.55%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $37.64K
YoY Change 742.06%
% of Gross Profit 809.46%
Operating Expenses $121.9K $96.86K
YoY Change 25.89% 22.54%
Operating Profit -$121.9K -$92.21K
YoY Change 32.24% 19.69%
Interest Expense $9.697K $20.63K
YoY Change -52.98% -78.08%
% of Operating Profit
Other Income/Expense, Net $84.29K $79.15K
YoY Change 6.49% -139.72%
Pretax Income -$13.06K
YoY Change -95.27%
Income Tax
% Of Pretax Income
Net Earnings -$37.65K -$13.06K
YoY Change 188.26% -95.27%
Net Earnings / Revenue -83.46%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 1.232B shares 1.232B shares 776.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $152.1K
YoY Change 747.71%
Cash & Equivalents $43.89K $152.1K
Short-Term Investments $10.00
Other Short-Term Assets
YoY Change
Inventory $0.00 $7.250K
Prepaid Expenses $0.00
Receivables $3.340K
Other Receivables $0.00
Total Short-Term Assets $46.39K $162.7K
YoY Change -71.48% 527.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $166.6K
YoY Change -100.0% 4435.25%
TOTAL ASSETS
Total Short-Term Assets $46.39K $162.7K
Total Long-Term Assets $0.00 $166.6K
Total Assets $46.39K $329.3K
YoY Change -85.91% 1011.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.344K
YoY Change -37.38%
Accrued Expenses $162.2K $126.3K
YoY Change 28.41% 4716.7%
Deferred Revenue
YoY Change
Short-Term Debt $333.2K
YoY Change -23.25%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.852M $1.475M
YoY Change 25.53% -9.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.852M $1.475M
Total Long-Term Liabilities $0.00
Total Liabilities $1.852M $1.475M
YoY Change 25.53% -9.25%
SHAREHOLDERS EQUITY
Retained Earnings -$8.792M -$7.996M
YoY Change 9.95% 6.28%
Common Stock $123.2K $77.65K
YoY Change 58.63% 484.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.805M -$1.146M
YoY Change
Total Liabilities & Shareholders Equity $46.39K $329.3K
YoY Change -85.91% 1011.94%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$37.65K -$13.06K
YoY Change 188.26% -95.27%
Depreciation, Depletion And Amortization $37.64K
YoY Change 742.06%
Cash From Operating Activities -$56.15K
YoY Change -15.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 168.1K
YoY Change 380.29%
NET CHANGE
Cash From Operating Activities -56.15K
Cash From Investing Activities
Cash From Financing Activities 168.1K
Net Change In Cash 111.9K
YoY Change -454.16%
FREE CASH FLOW
Cash From Operating Activities -$56.15K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
3283 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
300000 usd
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
300000 usd
CY2024Q3 bdpt Accrued Interest Current
AccruedInterestCurrent
163600 usd
CY2023Q4 bdpt Accrued Interest Current
AccruedInterestCurrent
139277 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1019 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1019 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
473501 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
443579 usd
CY2023Q4 bdpt Total Convertible Notes Payable
TotalConvertibleNotesPayable
374250 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
52592 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
321658 usd
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
28948 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
162177 usd
bdpt Amortization Of Debt Discount
AmortizationOfDebtDiscount
52592 usd
bdpt Amortization Of Debt Discount
AmortizationOfDebtDiscount
92318 usd
us-gaap Debt Instrument Convertible If Converted Value In Excess Of Principal
DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
63250 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
4727 usd
bdpt Convertible Shares Of Common Stock
ConvertibleSharesOfCommonStock
335968749 shares
bdpt Proceeds From Issuances Of Common Stock
ProceedsFromIssuancesOfCommonStock
134666 usd
bdpt Settled On Issuance Of Common Stock
SettledOnIssuanceOfCommonStock
-134666 usd
bdpt Loss On Derivative Instruments Related Convertible Notes
LossOnDerivativeInstrumentsRelatedConvertibleNotes
0 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-8644 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
3300 usd
CY2023Q4 bdpt Notes Payable To Related Parties Noncurrent
NotesPayableToRelatedPartiesNoncurrent
5144 usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
813 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1320 usd
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.04 pure
bdpt Term Of Notes Payable
TermOfNotesPayable
P1M
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
25429 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-24500 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-9988 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15441 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
898926387 shares
CY2024Q3 bdpt Working Capital Deficit
WorkingCapitalDeficit
-1805361 usd
CY2024Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
8882 usd
CY2024Q3 bdpt Convertible Note Payable Current
ConvertibleNotePayableCurrent
311000 usd
CY2023Q4 bdpt Convertible Note Payable Current
ConvertibleNotePayableCurrent
321658 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
31401 usd
bdpt Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rates
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRates
0 pure
CY2023 bdpt Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rates
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRates
0 pure
bdpt Gain Loss On Change In Fair Value Of The Derivative Liabilities
GainLossOnChangeInFairValueOfTheDerivativeLiabilities
185291 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0 usd
CY2022 bdpt Increase Decrease In Accrued Salaries Payable
IncreaseDecreaseInAccruedSalariesPayable
133334 usd
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
300000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24500 usd
bdpt Term Of Licenses Range Description
TermOfLicensesRangeDescription
The term of licenses is a range from 1 to 3 years for certain products
bdpt Amortization Expense
AmortizationExpense
1941 usd
bdpt Amortization Expense
AmortizationExpense
38989 usd
us-gaap Interest Expense Time Deposits
InterestExpenseTimeDeposits
2132 usd
CY2024Q3 us-gaap Security Deposit
SecurityDeposit
2500 usd
CY2024Q3 bdpt Discount On Convertible Notes
DiscountOnConvertibleNotes
0 usd
CY2023Q4 bdpt Discount On Convertible Notes
DiscountOnConvertibleNotes
52592 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1250000000 shares
us-gaap Notes Issued1
NotesIssued1
32096 usd
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.04 pure
CY2024Q3 bdpt Total Convertible Notes Payable
TotalConvertibleNotesPayable
311000 usd
CY2024Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
137955 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
18000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001575142
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1250000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1231728974 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
895760225 shares
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10000 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-54949
dei Entity Registrant Name
EntityRegistrantName
BioAdaptives Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2592228
dei Entity Address Address Line1
EntityAddressAddressLine1
2620 Regatta Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89128
dei City Area Code
CityAreaCode
702
dei Local Phone Number
LocalPhoneNumber
659-8829
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1231728974 shares
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43893 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60776 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
0 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
15281 usd
CY2024Q3 us-gaap Security Deposit
SecurityDeposit
2500 usd
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
2500 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
46393 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
88557 usd
CY2024Q3 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
0 usd
CY2023Q4 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
15441 usd
CY2024Q3 us-gaap Assets
Assets
46393 usd
CY2023Q4 us-gaap Assets
Assets
103998 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
473501 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
443579 usd
CY2024Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1028497 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
977872 usd
CY2024Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
311000 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
321658 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
32096 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 usd
CY2024Q3 bdpt Notes Payable Related Parties Classified As Current
NotesPayableRelatedPartiesClassifiedAsCurrent
6660 usd
CY2023Q4 bdpt Notes Payable Related Parties Classified As Current
NotesPayableRelatedPartiesClassifiedAsCurrent
7520 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1851754 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1750629 usd
CY2024Q3 us-gaap Liabilities
Liabilities
1851754 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1750629 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1231728974 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
895760225 shares
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10000 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
123173 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
89576 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6861859 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6527428 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8791518 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8264145 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1805361 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1646631 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46393 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103998 usd
CY2024Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Revenues
Revenues
15649 usd
us-gaap Revenues
Revenues
12669 usd
us-gaap Revenues
Revenues
21364 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
10999 usd
us-gaap Cost Of Revenue
CostOfRevenue
8639 usd
us-gaap Cost Of Revenue
CostOfRevenue
13244 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
4650 usd
us-gaap Gross Profit
GrossProfit
4030 usd
us-gaap Gross Profit
GrossProfit
8120 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40396 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33706 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
76685 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
60258 usd
CY2024Q3 us-gaap Professional Fees
ProfessionalFees
21545 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
25514 usd
us-gaap Professional Fees
ProfessionalFees
90805 usd
us-gaap Professional Fees
ProfessionalFees
76010 usd
CY2024Q3 bdpt Impairment Of Inventory
ImpairmentOfInventory
60000 usd
CY2023Q3 bdpt Impairment Of Inventory
ImpairmentOfInventory
0 usd
bdpt Impairment Of Inventory
ImpairmentOfInventory
81350 usd
bdpt Impairment Of Inventory
ImpairmentOfInventory
0 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
37643 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
19941 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
38989 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
121941 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
96863 usd
us-gaap Operating Expenses
OperatingExpenses
268781 usd
us-gaap Operating Expenses
OperatingExpenses
175257 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-121941 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-92213 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-264751 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-167137 usd
CY2024Q3 us-gaap Other Income
OtherIncome
0 usd
CY2023Q3 us-gaap Other Income
OtherIncome
0 usd
us-gaap Other Income
OtherIncome
4950 usd
us-gaap Other Income
OtherIncome
0 usd
CY2024Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-11 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
0 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-31 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
9697 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
20625 usd
us-gaap Interest Expense
InterestExpense
82281 usd
us-gaap Interest Expense
InterestExpense
123941 usd
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
93989 usd
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
261488 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-185291 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
8644 usd
CY2024Q3 us-gaap Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1
DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1
0 usd
CY2023Q3 us-gaap Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1
DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1
-161700 usd
us-gaap Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1
DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1
0 usd
us-gaap Debtor Reorganization Items Gain Loss On Settlement Of Other Claims Net1
DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet1
-161700 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
84292 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
79152 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-262622 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-277028 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-37649 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-13061 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-527373 usd
us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-444165 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-37649 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13061 usd
us-gaap Net Income Loss
NetIncomeLoss
-527373 usd
us-gaap Net Income Loss
NetIncomeLoss
-444165 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
895760225 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
730006523 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1147557292 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
482799498 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1646631 usd
CY2024Q1 bdpt Series A Preferred Stock Issued For License Fee Amount
SeriesAPreferredStockIssuedForLicenseFeeAmount
1500 usd
CY2024Q1 bdpt Series B Preferred Stock Issued For License Fee Amount
SeriesBPreferredStockIssuedForLicenseFeeAmount
3000 usd
CY2024Q1 bdpt Series B Preferred Stock Issued For Settlement Of Debt Amount
SeriesBPreferredStockIssuedForSettlementOfDebtAmount
1500 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
149455 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-306707 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1797883 usd
CY2024Q2 bdpt Series C Preferred Stock Issued For Purchase Of Inventory Amount
SeriesCPreferredStockIssuedForPurchaseOfInventoryAmount
60000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
53188 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-183017 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1867712 usd
CY2024Q3 bdpt Stock Issued During Period Value Conversion Of Convertible Securities Series D
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesSeriesD
100000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-37649 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-1805361 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1451501 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
108036 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-287187 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1630652 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
96057 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-143917 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1678512 usd
CY2023Q3 bdpt Series A Preferred Stock Issued For License Fee Amount
SeriesAPreferredStockIssuedForLicenseFeeAmount
22625 usd
CY2023Q3 bdpt Series B Preferred Stock Issued For Settlement Of Debt Related Party Amount
SeriesBPreferredStockIssuedForSettlementOfDebtRelatedPartyAmount
165000 usd
CY2023Q3 bdpt Series B Preferred Stock Issued For License Fee Amount
SeriesBPreferredStockIssuedForLicenseFeeAmount
180000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
178100 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-13061 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1145848 usd
us-gaap Profit Loss
ProfitLoss
527373 usd
us-gaap Profit Loss
ProfitLoss
444165 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
185291 usd
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-8644 usd
us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
18000 usd
us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
0 usd
bdpt Impairment Of Inventory
ImpairmentOfInventory
81350 usd
bdpt Impairment Of Inventory
ImpairmentOfInventory
0 usd
bdpt Amortization Of Other Intangible Assets
AmortizationOfOtherIntangibleAssets
1941 usd
bdpt Amortization Of Other Intangible Assets
AmortizationOfOtherIntangibleAssets
38989 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
52592 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
92318 usd
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
0 usd
us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
-161700 usd
bdpt Unrealized Gains Loss On Marketable Securities Cost Method Investments And Other Investments
UnrealizedGainsLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
0 usd
bdpt Unrealized Gains Loss On Marketable Securities Cost Method Investments And Other Investments
UnrealizedGainsLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments
-31 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3344 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6069 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1627 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-10000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
0 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
35289 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
29481 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
0 usd
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-470 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-148979 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-132477 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
178100 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
51044 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
50000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
32096 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
80000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
100000 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
132096 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
259144 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-16883 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
126667 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60776 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25405 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43893 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
152072 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
bdpt Derivative Liability Recognized As Debt Discount
DerivativeLiabilityRecognizedAsDebtDiscount
0 usd
bdpt Derivative Liability Recognized As Debt Discount
DerivativeLiabilityRecognizedAsDebtDiscount
150000 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
202643 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
204093 usd
bdpt Series A Preferred Stock Issued For License Fee
SeriesAPreferredStockIssuedForLicenseFee
1500 usd
bdpt Series A Preferred Stock Issued For License Fee
SeriesAPreferredStockIssuedForLicenseFee
22625 usd
bdpt Series B Preferred Stock Issued For License Fee
SeriesBPreferredStockIssuedForLicenseFee
3000 usd
bdpt Series B Preferred Stock Issued For License Fee
SeriesBPreferredStockIssuedForLicenseFee
180000 usd
bdpt Issuance Series B Preferred Stock For Settlement Of Debt Related Party
IssuanceSeriesBPreferredStockForSettlementOfDebtRelatedParty
0 usd
bdpt Issuance Series B Preferred Stock For Settlement Of Debt Related Party
IssuanceSeriesBPreferredStockForSettlementOfDebtRelatedParty
165000 usd
bdpt Issuance Series C Preferred Stock For Purchase Of Inventory
IssuanceSeriesCPreferredStockForPurchaseOfInventory
60000 usd
bdpt Issuance Series C Preferred Stock For Purchase Of Inventory
IssuanceSeriesCPreferredStockForPurchaseOfInventory
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2401250328 shares
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8791518 usd
CY2024Q3 us-gaap Credit Card Receivables
CreditCardReceivables
0 usd
CY2023Q4 us-gaap Credit Card Receivables
CreditCardReceivables
0 usd
us-gaap Debt Instrument Term
DebtInstrumentTerm
P12M
us-gaap Interest Expense Other
InterestExpenseOther
607 usd
CY2024Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
311000 usd
bdpt Beginning Balance
BeginningBalance
977872 usd
bdpt Derivatives Recognition Debt Discounts
DerivativesRecognitionDebtDiscounts
0 usd
bdpt Addition Of New Derivatives Recognized As Loss On Derivatives
AdditionOfNewDerivativesRecognizedAsLossOnDerivatives
0 usd
bdpt Gain Loss On Change In Fair Value Of The Derivative Liabilities
GainLossOnChangeInFairValueOfTheDerivativeLiabilities
185291 usd
bdpt Ending Balance
EndingBalance
1028497 usd
bdpt Loss On Derivative Instruments Related Convertible Notes
LossOnDerivativeInstrumentsRelatedConvertibleNotes
578213 usd
bdpt Gain Loss On Change In Fair Value Of The Derivative Liabilities
GainLossOnChangeInFairValueOfTheDerivativeLiabilities
-586857 usd
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
185291 usd
us-gaap Interest Paid
InterestPaid
134 usd
us-gaap Interest Paid
InterestPaid
54 usd
CY2024Q3 bdpt Notes Payable To Related Parties Noncurrent
NotesPayableToRelatedPartiesNoncurrent
4284 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd

Files In Submission

Name View Source Status
0001640334-24-001752-index-headers.html Edgar Link pending
0001640334-24-001752-index.html Edgar Link pending
0001640334-24-001752.txt Edgar Link pending
0001640334-24-001752-xbrl.zip Edgar Link pending
bdpt-20240930.xsd Edgar Link pending
bdpt-20240930_lab.xml Edgar Link unprocessable
bdpt_10q.htm Edgar Link pending
bdpt_10qimg2.jpg Edgar Link pending
bdpt_ex311.htm Edgar Link pending
bdpt_ex312.htm Edgar Link pending
bdpt-20240930_pre.xml Edgar Link unprocessable
bdpt_10q_htm.xml Edgar Link completed
bdpt_ex321.htm Edgar Link pending
bdpt_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bdpt-20240930_cal.xml Edgar Link unprocessable
bdpt-20240930_def.xml Edgar Link unprocessable